Menu

Top Stories

Published on Tuesday, November 6, 2018

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma and TAP work together in clinical study

Mereo BioPharma Group plc announced a collaboration with (and investment from) the venture philanthropy arm of the Alpha-1 Foundation, The Alpha-1 Project, Inc. (TAP) in Mereo’s MPH-966 development program.

MPH-966 is an oral neutrophil elastase inhibitor that specifically targets the neutrophil elastase which is primarily responsible for the lung degradation in Alpha-1 patients.

TAP investment was announced in Mereo’s November 5th press release, publicizing that the first Alpha-1 patient was dosed in their Phase 2 clinical study of MPH-966 (alvelestat). The study is a 12-week randomized, placebo controlled, clinical trial evaluating two doses of MPH-966 in approximately 165 patients with the ZZ or NULL genetic mutations of Alpha-1. These mutations are associated with the more severely affected patients who have very low (ZZ) or zero (NULL) alpha-1 antitrypsin levels.

“We are very pleased that the first patient has been successfully dosed in this phase 2 study in Alpha-1 Antitrypsin Deficiency. We are excited by the potential for a new oral therapeutic to improve the lives of our patients with this debilitating disease and are pleased to be supporting Mereo with this phase 2 study,” said Jean-Marc Quach, president and CEO of TAP.

The study is being conducted in the United States and Europe with top line data expected in the second half of 2019. If the results are positive, Mereo intends to seek regulatory advice on the design of a pivotal trial.

To read the full press release, please click here.

Source: Mereo BioPharma Group plc


Print

Uncertainty added to health insurance markets

Friday, October 13, 2017
It has been an eventful 24 hours in Washington as President Trump made a number of announcements related to health insurance policy.  First, he signed an executive order that seeks to increase competition by facilitating access to association...
Divider

Celebrating plasma donors worldwide

Wednesday, October 11, 2017
International Plasma Awareness Week (IPAW) brings awareness to the importance of plasma donors worldwide. “During PPTA’s International Plasma Awareness Week, we want to thank all the donors that make life sustaining Alpha–1...
Divider

Medicare says 2018 to offer more health coverage choices and decreased premiums

Friday, September 29, 2017
Today, the Centers for Medicare & Medicaid Services (CMS) announced that people with Medicare will have more choices and options for their Medicare coverage in 2018. As CMS releases the benefit and premium information for Medicare health and...
Divider

Record-breaking year for Team Alpha-1 at Escape to the Cape

Friday, September 29, 2017
As summer wanes and fall begins, Team Alpha–1 is decompressing from another successful Autumn Escape Bike Trek. This year has seen many firsts over our 23-year history of participating in this event with the American Lung Association of the...
Divider

Bob Campbell passes away, Foundation Communications Director, former AlphaNet Coordinator

Friday, July 28, 2017
Our dear friend and colleague, Bob Campbell passed Thursday evening with his wife Elizabeth by his side. Campbell began his Alpha-1 journey when he was diagnosed by his allergist. In 2002, he took the leap and became an AlphaNet...
Divider

Kamada Submits Proposed Phase 3 Protocol to FDA for Inhaled Alpha-1 Antitrypsin Treatment

Friday, July 21, 2017
Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, today announced that the Company has submitted to the U.S. Food and Drug Administration (FDA) for review a proposed pivotal Phase 3 protocol for its...
Divider

Foundation president and CEO urges Alphas to find their place in the Alpha-1 Community

Thursday, June 29, 2017
CHICAGO, Illinois – Henry Moehring, president and CEO of the Alpha–1 Foundation, presided over the 26th and largest National Education Conference of the Alpha–1 community since its inception, he said in his Foundation update...
Divider

Alpha-1 Foundation Accepting Proposals for the John W. Walsh Translational Research Award in Alpha-1 Antitrypsin Deficiency

Wednesday, June 28, 2017
The Alpha-1 Foundation is committed to finding a cure for Alpha-1 Antitrypsin Deficiency and to improving the lives of people affected by Alpha-1 worldwide. This award is named after John W. Walsh, who dedicated his life’s work to finding...
Divider

Barbara Pusey honored in memoriam at Alpha–1 awards and recognition night

Monday, June 26, 2017
Barbara Pusey, who was the first AlphaNet Coordinator for the augmentation therapy marketed in the United States as Zemaira and was a major influence in building the AlphaNet Zemaira program into what it is today, was recognized posthumously, with...
Divider

Grifols announces $1 million grant to support Alpha-1 Foundation’s John W. Walsh Research Fund

Monday, June 26, 2017
Washington, DC  — Grifols announced that it will award a million-dollar grant to support the John. W. Walsh Research Fund, the Foundation’s peer-reviewed research program named in honor of Walsh, the Foundation’s co-founder...
Divider

More Than 600 to Hear Top World Experts on Alpha-1 at National Conference in Chicago

Monday, June 5, 2017
CHICAGO, June 5, 2017 – More than 600 people with Alpha–1 Antitrypsin Deficiency – the most common known genetic cause of chronic obstructive pulmonary disease (COPD) – along with their family members, caregivers and...
Divider

Alpha highlights research participation for Rare Disease Day

Tuesday, February 28, 2017
Ken Benson is a firm believer in research. Ken Benson For years, the lung- and liver-affected Alpha has allowed scientists to closely examine how his body works in study after study. He has participated in the COPDGene study at the...
Divider
123456789

Article Search

Enter keywords in text box and click Search button for results.